65,437 trials
Obsessive-Compulsive Disorder
Primary: Change in Obsessive and Compulsive Symptom Severity (Yale-Brown Obsessive Compulsive Scale) — -39.4 Percent change
Chronic Pain
Primary: Patient Diary-derived Numeric Rating Scale (NRS) Pain Intensity Change From Baseline to Week 12 or Final Visit of the Double-blind Phase — 0.6; 0.6 units on a scale
Anesthesia
Primary: Average Pain Intensity Pre- and Post-Ketamine Induction — 7.9; 1.6; 4.1; 4.3 score on a scale
Myopia
Primary: Lens Surface Wettability — 3.26; 3.26 units on a scale
Corneal Foreign Body
Primary: Success Rate — 1 Participants
Anemia · End Stage Renal Disease (ESRD)
Primary: Change From Baseline (BL) to the Average Hemoglobin (Hb) in Weeks 28-36 Without Rescue Therapy [EU (EMA)] — 0.428; 0.193 g/dL — p=<0.001
Chronic Peridontitis Patients · Chronic Gingivitis · Healthy
Primary: Pocket Depth — 1.60; 2.50; 6.75 millimetres
Diabetes
Primary: Number of Participants Who Developed Foot Ulcer During Study Time Frame — 76; 82 Participants
Healthy Adults
Primary: Recognition Memory Assessed by a Retrieval Memory Experiment — 48.47; 34.78; 33.983 percentage of correctly recalled old fac
Impaired Glucose Tolerance
Primary: Post Meal Glucose Area Under the Curve — 508; 513 mg*hr/dL
Advanced Solid Tumors · Lymphoma
Primary: Part A: Cmax: Maximum Observed Plasma Concentration for Ixazomib — 89.06 nanogram per milliliter (ng/mL)
Chronic Disease · Medication Adherence
Primary: Medication Adherence at 1 Month — 11.83; 10.20; 9.33 score on a scale
Brain Cancer · Pediatric Cancers
Primary: Objective Response Rate — 0 Percentage of Participants
Plaque Psoriasis
Primary: Change in Physicians Global Assessment (PGA) From Baseline to Week 2 and Week 4 — 20; 0; 0; 0 Participants
Cardiopulmonary Bypass
Primary: Total Transfusion Amounts — 161; 116 mililiters — p=0.35